Celltrion Announces Clinical Results of Remsima SC at ECCO... Praised by Medical Professionals

2025 ECCO Celltrion Booth. Photo by Celltrion

Celltrion announced on the 21st that it participated in the '2025 European Crohn’s and Colitis Organization (ECCO)' held over four days from the 19th to the 22nd in Berlin, Germany.

Celebrating its 20th edition this year, ECCO is one of the core global conferences on Inflammatory Bowel Diseases (IBD). It is a platform for sharing the latest research, clinical information, and trends in therapeutic development related to the disease. This year, with over 8,000 IBD experts from around the world attending, Celltrion is the only Korean company to open a dedicated promotional booth, conducting various marketing activities that attract significant attention from participants.

First, Professor Jean-Fr?d?ric Colombel from the Icahn School of Medicine at Mount Sinai in New York gave an oral presentation on post hoc analysis data from a Phase 3 clinical trial evaluating endoscopic and histologic outcomes in patients with moderate to severe Ulcerative Colitis (UC) treated with infliximab, focusing on maintenance therapy with 'Remsima SC' (generic name: infliximab; U.S. brand name: Zimpenra).

The analysis showed that at week 54, the Remsima SC maintenance therapy group demonstrated significantly higher endoscopic and histologic improvements compared to the placebo group. Additionally, the simultaneous achievement rates of endoscopic normalization and histologic remission continuously increased in the Remsima SC maintenance group, and endoscopic normalization rates improved over time. This presentation drew great interest and positive responses from attendees as it newly confirmed the benefits of Remsima SC maintenance therapy in UC patients.

Furthermore, on the 21st, Celltrion unveiled three posters related to the post hoc analysis of the Remsima SC Phase 3 clinical trial results, covering topics such as 'dose escalation after loss of response,' 'efficacy according to intestinal disease location,' and 'immunogenicity impact in moderate to severe Crohn’s Disease (CD) patients.' These additional efficacy data are expected to further enhance healthcare professionals’ trust in the product and their prescribing preferences.

Also on the same day, a symposium titled 'Early Treatment of Inflammatory Bowel Disease Patients: Utilizing Advanced Therapies at the Appropriate Time' was held. The symposium explained the concept and importance of early treatment and featured in-depth discussions between presenters and panelists on the potential benefits of early treatment using Remsima SC.

At the Celltrion exclusive booth, expert seminars were conducted, sequentially revealing two research results: 'Long-term treatment effects of Remsima SC in IBD therapy' and 'Real-world prescription data of Remsima SC in patient cases such as fistulizing Crohn’s disease and obesity.'

Meanwhile, Celltrion plans to actively leverage the heightened interest from local IBD specialists following the launch of 'Stekima' (generic name: ustekinumab) at the end of last year, which brought its portfolio to four IBD therapeutics. Celltrion’s Global Sales Division CEO and Vice Chairman, Kim Hyung-ki, is personally leading marketing activities on-site, holding meetings with leading global IBD scholars. Additionally, a dedicated meeting space within the booth facilitates various meetings with local healthcare professionals. The strategy is to increase prescription preference through active engagement with medical staff, thereby driving actual sales growth.

Ha Tae-hoon, Head of Celltrion’s European Headquarters, stated, "With the continuous release of diverse research data on Remsima SC, the number of visitors to our booth has increased by more than 1.5 times compared to previous years. Celltrion has established itself as a trusted partner closely collaborating with European IBD specialists, not just a simple pharmaceutical supplier, by utilizing direct sales networks across 20 subsidiaries in Europe. We will continue to maintain these cooperative relationships to further strengthen our leadership and market dominance."

This content was produced with the assistance of AI translation services.